T

here was an excitement evident at this week’s meeting of stem cell scientists in Boston, with speakers highlighting how the years of toil in labs were approaching payoffs for patients, as more cell therapies have moved into clinical trials and researchers have gained a greater understanding of how to maximize their promise.

“This is our century,” Sally Temple, the president of the International Society for Stem Cell Research, said as thousands of experts milled about.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.